Ardea Biosciences (RDEA) Completes Common Stock Offering, Gross Proceeds $166.2 Million
Down)
Ardea Biosciences, Inc. (NASDAQ: RDEA) announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters.
All of the shares were offered by Ardea at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering were approximately $166.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ardea.
Ardea anticipates using the net proceeds from the offering for general corporate purposes, which may include research and development expenses, including expenses related to Phase 3 clinical trials of lesinurad, capital expenditures, working capital, and general and administrative expenses.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
All of the shares were offered by Ardea at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering were approximately $166.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ardea.
Ardea anticipates using the net proceeds from the offering for general corporate purposes, which may include research and development expenses, including expenses related to Phase 3 clinical trials of lesinurad, capital expenditures, working capital, and general and administrative expenses.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Regency Energy Partners (RGP) Files $200M Common Unit Shelf
- New York Mortgage Trust (NYMT) Announces 4M Common Offering
- Peoples Bancorp (PEBO) Files $100M Mixed Shelf
Create E-mail Alert Related Categories
Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
